stock poised for private equity takeover By Investing.com
Avid Bioservices, Inc. (NASDAQ:), a biopharmaceutical company specializing in the development and manufacturing of biologic products, has recently become the subject of significant market attention. With a market capitalization of $787 million and an impressive 130% return over the past year according to InvestingPro data, the company has captured investors’ interest despite challenging profitability metrics. The company, which provides contract development and manufacturing organization (CDMO) services, has experienced a series of notable events that have reshaped its market position and future outlook.
Financial Performance and Guidance
Avid Bioservices has demonstrated a mixed financial performance in recent quarters. In the fourth…
